ANATOLE BESARAB, M.D.

Undergraduate:

1961-65 B.S. Chemical Engineering, University of Pennsylvania

Medical School:

1965-69 M.D., University of Pennsylvania

Postgraduate:

1969-70 Intern in Medicine, Pennsylvania Hospital, Phila., PA
1970-72 Resident in Medicine, Pennsylvania Hospital, Phila., PA
1972-73 Fellow in Nephrology, Harvard Medical School, Boston City Hospital, Boston MA. (Dr. F. Epstein)
1972-73 Chief Resident, Thorndike Clinical Research Center, Harvard Medical School, Boston City Hospital, Boston, MA
1973-75 Fellow in Nephrology, Harvard Medical School, Beth Israel Hospital, Boston, MA. (Dr. F. Epstein)

CERTIFICATION

June 21, 1972 American Board of Internal Medicine
October 19, 1976 American Board of Nephrology


HONORS

1964 Tau Beta Pi (National Engineering Honor Society)
1965 Cum Laude, University of Pennsylvania
1972-74 Recipient NIH-Special Research Fellowship Award
1982 Fellow American College of Physicians

PROFESSIONAL MEMBERSHIPS

National American Association for the Advancement of Science
American College of Physicians
American Society for Artificial Internal Organs
Member Regulatory Affairs Committee, ASAIO 1992-1994
Program Committee 1994-1995
Abstract Selection Committee, 1995
American Society for Clinical Research
American Society of Nephrology
Abstract Selection Committee 1996
Task force on Research 1998
Abstract Selection Committee 1999
Section Chair, Complications of Dialysis
Co-chair, ASN Course:Expanding our Procedural Portfolio Course, 1999
Co-Chair, ASN Course: Hands on Nephrology, 2000
Co-Chair, ASN Course: 2001
National Kidney Foundation
Vice-Chairman Vascular Access Committee DOQI 1995-1997
Member, HCFA panel on Clinical Performance Measures development for vascular access for hemodialysis
Member FORUM of ESRD Networks – Vascular Access
New York Academy of Sciences
Renal Physicians Association

INTERNATIONAL
International Society of Nephrology

PUBLICATIONS:.(1997- present)
  1. Sherman R, Besarab A, , Schwab SJ, Beathard GA. Recognition of the failing vascular access: A current perspective.
  2. Seminars Dialysis 1997; 10:1-5.
  3. Besarab A, Sherman R. The relationship of recirculation to access blood flow. Am J Kid Dis 1997: 29: 223-229.
  4. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Editorial Review. Kidney Int. 1997; 51: 623-630.
  5. Sullivan KL, Besarab A. - Hemodynamic screening and early percutaneous intervention reduce hemodialysis access thrombosis and increase graft longevity. J Vasc Interv Radiol 1997;8:163-70.
  6. Besarab A, Ross R, Frinak S, Zasuwa G. Increased Urea Kinetic Modeling Volume: Possible mechanisms and its significance. ASAIO Journal 1997; 43:303-310.
  7. Schwab S, Besarab A, Beathard G, et al. NKF-DOQI: Clinical practice guidelines for vascular access. Am J Kid Dis 1997; 30 (Suppl 3): S150-S189.
  8. Nissenson AR, Besarab A, Bolton WK, Goodkin DA, Schwab SJ. Target Hemoglobin Hematocrit during EPO therapy.
  9. Nephrol Dial Transplant 1997, 14: 1813-1816.
  10. Erslev A, Besarab A, Ballas SK. Erythropoiesis and erythropoietin production in renal and sickle cell anemia. Gematol. Tranfuziol 1997; 42:13-15. 1077. [In Russian]
  11. Besarab A, Lubkowski T, Frinak S, Ramanathan S, Escobar F. Detecting vascular access dysfunction. ASAIO Journal 1997; 43:M539-M543.
  12. Besarab A, Lubkowski T, Frinak S, Ramanathan S, Escobar F. Detection of strictures and vascular outlet stenoses in vascular accesses: Which test is best?. ASAIO Journal 1997; 43:M543-M547.
  13. Besarab A, Frinak S. The prevention of access failure: Pressure Monitoring. ASAIO Journal 1998; 44: 35-37.
  14. Besarab A, Frinak S, Sherman RA, Goldman J, Dumler F, DeVita MV, Kapoian T, Al-Saghir F, Lubkowski T. Simplified measurement of intra-access pressure. J Am Soc Nephrol 1998: 9:284-289.
  15. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamaoto DM, Schwab SC, Goodkin DA. The effects of normal versus anemic hematocrit on hemodialysis patients with cardiac disease. N Eng J Med 1998:339:584-590.
  16. Wish J, Roberts J, Besarab A, Owen WF. The cost of implementing the DOQI clinical practice Guidelines. Adv Ren Replace Ther 1999 6:67-74.
  17. Escobar FS III, Schwartz SA, Abouljoud M, Douzdian V, Escobar MD, Besarab A, Elliot JP. New ÒhoodedÓ versus conventional ePTFE graft in haemodialysis patients. Int Rev Modern Surgery 1999.
  18. Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee, J, Anandan JV. Dialysate Iron therapy. Infusion of soluble ferric pyprophosphate via the dialysate during hemodialysis. Kidney Int 1999; 55:1891-1898.
  19. Besarab A, Escobar FS III. A Glimmer of hope: Increasing the construction and maturation of autologous arteriovenous fistulas. [Editorial] Am J Kid Dis 1999; 33:977-979.
  20. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999: 34:21-28.
  21. Besarab A. Parenteral iron therapy: Safety and efficacy. Seminars Dialysis 1999: 12: 237-242.
  22. Besarab A. Monitoring Vascular Access Flow. Lots of methods but how should we use the information. [Editorial] Adv Ren Replace Ther 1999; 6:: (July); web only
  23. Besarab A, Frinak S, Yee J. An indistinct balance: Safety and efficacy of parenteral iron. J Am Soc Nephrol 1999: 34: 2029-2043
  24. Besarab A. Iron and cardiac disease in end-stage renal disease setting. Am J Kidney Dis 1999; 34 (Suppl. 2): S18-S24.
  25. Besarab A. Vascular Access in Europe and the United States: Striking contrasts. Contemp Dial Nephrol 1999; 20(10):22-28
  26. Besarab A, Amin N, Ahsan M, Vogel SE, Zasuwa G, Frinak S, Zazra J, Anandan JV, Gupta, AJ. Optimization of epoetin therapy with intravenous iron in hemodialysis patients. J Am Soc Nephrol 2000; 11:530-538.
  27. Besarab A. Physiologic and pharmacodynamic considerations for route of EPO administration Semin Nephrol 2000; 20: 364-374.
  28. Besarab A, Levin, A. Defining a Renal Anemia Management Period. Am J Kidney Disease 2000; 36 (Suppl 3): S13-S23.
  29. Besarab A, Adams M, Amatucci S, Bowe D, Deane J, Ketchen K, Reynolds K, Tello A. Unraveling the Realities of Vascular Access: The Network 11 Experience. Adv Renal Replace Ther 2000; 4 (Suppl 1): S65-70.
  30. Besarab A, Aslam MA. Should the hematocrit (hemoglobin) be normalizing in pre-ESRD or dialysis patients? Yes! Blood Purif 2001; 19:168-175
  31. Besarab A, Lubkowski T, Vu A, M Aslam, Frinak S. Determinants of vascular access flow. ASAIO Journal 2001; (in Print).
  32. Rebecca J Schmidt, DO and Anatole Besarab, MD. When to treat the anemia of chronic renal insufficiency. Family Practice recertification 23:38-46, 2001.
  33. Besarab A, Schmidt RJ. Renal Anemia Management Period. JAMA in prep

    CHAPTERS IN BOOKS & MONOGRAMS

    1 Bixler JH, Nelson LM, and Besarab A. The Diaphron hemodiafilter: An alternative to dialysis for extracorporeal blood purification. Symposium series: "The Artificial Kidney" R. Dedrick, Ed., Am Institute Chem Eng. New York, 1968.
    2 Besarab, A: What is the optimal use of rHuEPO in the Anemia of end stage renal disease. Proceedings of the IV Asian -Pacific Congress of Nephrology. Editors Zhang Jinhong, Du Xuehai, Liu Zhihong, Li Leishi. International Academic Publishers:563-567, Beijing, China. October 15-21, 1990.
    3 Besarab, A. & McCrea, JB: Anemia in ESRD Patients. In: Dialysis Therapy, 2nd Edition, Eds. Nissenson, A and Fine, R. Hanley & Belfiro, Inc.:pp223-225, Philadelphia, PA., 1993.
    4 Besarab, A. & McCrea, JB: EPO use in ESRD Patients. In: Dialysis Therapy, 2nd Edition, Eds. Nissenson, A and Fine, R. Hanley & Belfiro, Inc.pp:225-227, Philadelphia, PA., 1993.
    5 Besarab A. The Pharmacology of Epoetin Dose. Quebec Conference Proceedings on Recombinant Human Erythropoietin (r-HuEPO). Science & Medicine, Canada, pp 4-9, Ontario Canada.
    6 Sullivan K, Besarab A. Strategies for maintaining dialysis access patency. Chapter 11. In: Current techniques in Interventional Radiology. Second edition. Ed. Cope, C. Current Medicine, Philadelphia PA. 1995: pp. 125-131.
    7 Besarab A: Hematologic Aspects of Uremia. In: Clinical Dialysis, 3rd edition, Eds. Nissenson AR, Fine RN, and Gentile DE. Appleton and Lange, Norwalk, CT 1995: pp 618-651.
    8 Besarab, A. Anemia-associated outcomes in ESRD: Cardiovascular risk, functional capacity, and rehabilitation. In: Bridging the Gap: Bringing research to practice. Triclinica Communications, New York, NY 1995: p2-5.
    9 Erythropoiesis and epoetin alfa dosing. Nissenson AR, Besarab A (EDS) mL Medcom. 1996
    10 Besarab A.. Anemia in Renal Disease. In: Diseases of the Kidney, 5th Ed. . Eds. Schrier, Gottschalk.. Little, Brown, and Co, Boston MA. 1997; pp 2581-2596.
    11 Besarab A, Frinak S, Dumler F, Goldman J, DeVita MV, Sherman R. Simplified intra-access pressure measurement. Angioaccess for Hemodialysis: Proceedings of an International Multidisciplinary Symposium held at Tours, France, June 3-5 1996. Edited by P. Bourquelot. Gambro & Guerbet Publication, Paris 1997.
    12 Schwab S, Besarab A, Beathard G, et al. In: NKF-DOQI: Clinical practice guidelines for vascular access. New York, National Kidney Foundation, 1997.
    13 Besarab A, Samarapungavan D. Treatment of Anemia in Dialysis Patients. In: Principles and Practice of Dialysis, Ed. Henrich WL, Williams and Wilkens, Baltimore, 1998; pp398-436.
    14 Besarab A. Native fistulae versus grafts in the DOQI: A NephrologistÕs perspective. AngioAccess for Hemodialysis. Proceedings of the 2nd International Multidisciplinary Symposium, Tours. France May31-June 2, 1999, pp 10-12.
    15 Besarab A. Intra-access pressure measurements. AngioAccess for Hemodialysis. Proceedings of the 2nd International Multidisciplinary Symposium, Tours. France May31-June 2, 1999, pp 13-15.
    16 Besarab A, Parasurman RPK, Frinak S. Vascular Access for Hemodialysis. In: Updated Textbook of Clinical Nephrology, Dialysis, and Transplantation, Ed. Harmut H. Malluche, Dustri-Verlag, Munich,1999. Chapter ll-2.
    17 Besarab A, Dunfee T Frinak S. The DOQI Guidelines for Vascular Access – What is practical? In Henry M, ed. Vascular Access for Hemodialysis. VI; pp 173-188, 1999.
    18 Escobar FS III, Schwartz SA, Abouljoud M, Douzdian V, Escobar MD, Besarab A, Elliot JP. A preliminary study comparing a new ÒhoodedÓ vs. conventional ePTFE graft in hemodialysis patients. In Henry M, ed. Vascular Access for Hemodialysis. VI; pp 205-211, 1999.
    19 Besarab A, Frinak S. Strategies For Prospective Detection of Graft Dysfunction. In: Hemodialysis Vascular access, Eds: Schwab, Conlon, Nicholson. Oxford University Press, Oxford, England, 2000; pp 157-.182.
    20 Besarab A, Rasa R. Vascular Access for Hemodialysis. In: Handbook of Dialysis, 3rd edition, Eds: Daurgirdas JT, Blake PG, Ing TS.Lippincott, William, & wilkens, Philadelphia, Pa, 2000;. pp 67-101.
    21 Schmidt R, Besarab A. Epoetin Use in Hemodialysis Patients. In: Dialysis Therapy, 3rd Edition, Eds. Nissenson, A. (in print)
    22 Besarab A, Schmidt R. Anemia in Patients with End Stage Renal Disease. In: Dialysis Therapy, 3rd Edition, Eds. Nissenson, A. (In print)
    23 Besarab A, Frinak S, Aslam M. Pressure Measurements in the surveillance of vascular accesses. (in press)
Copyright 2001 Henry Ford Health System